Magda Marquet
Magda Marquet's purchase track record
Magda Marquet has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/31/2023 | IMMX | $49K | +151.7% | +65.0% | +13.1% |
| 12/15/2022 | ARCT | $40K | -12.9% | +50.7% | +13.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
IMMX Holds Shareholder and Analyst Call. Immix Biopharma hosted a shareholder and analyst conference call, sharing recent company updates and answering questions. The discussion gave participants insight into the company's current activities and outlook. Such calls can influence how investors view the business and its progress.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
AnaptysBio News Mixes Valuation Views With Litigation Risks. Recent articles highlight a split in opinion on AnaptysBio. Some sources argue the stock is undervalued based on its royalty model, while others point to significant litigation uncertainty. This debate occurs as the stock has seen a substantial rise, though it currently trades near its 52-week high.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Arcturus Shares Rise on Phase II Data and Analyst Upgrades. Arcturus Therapeutics reported positive Phase II data for ARCT-810 and introduced a new over-the-counter therapy platform. These updates coincided with Citigroup upgrading the stock to Buy and raising its price target to $20. The company also discussed progress in its mRNA liver therapeutics platform, contributing to the recent share price movement.
Transaction History
| TRAX | ▲ Buy | Option Exercise | 6,030 | $0 | 6/15/2026 | View on chart |
| IMMX | ▲ Buy | Grant | 6,250 | $0 | 5/22/2026 | View on chart |
| ANAB | ▲ Buy | Option Exercise | 11,000 | $287K | 1/15/2026 | View on chart |
| ANAB | ▼ Sell | Open Market | 9,290 | $447K | 1/15/2026 | View on chart |
| ANAB | ▼ Sell | Open Market | 1,710 | $84K | 1/15/2026 | View on chart |
| ANAB | ▲ Buy | Option Exercise | 6,030 | $0 | 6/15/2025 | View on chart |
| ANAB | ▲ Buy | Option Exercise | 3,900 | $0 | 6/15/2024 | View on chart |
| ARCT | ▲ Buy | Option Exercise | 3,131 | $0 | 6/14/2024 | View on chart |
| IMMX | ▲ Buy | Grant | 21,155 | — | 5/20/2024 | View on chart |
| IMMX | ▲ Buy | Grant | 25,002 | $0 | 5/15/2024 | View on chart |
| IMMX | ▲ Buy | Open Market | 9,000 | $22K | 9/6/2023 | View on chart |
| IMMX | ▲ Buy | Open Market | 10,000 | $25K | 9/5/2023 | View on chart |
| IMMX | ▲ Buy | Open Market | 1,000 | $2K | 8/31/2023 | View on chart |
| ARCT | ▲ Buy | Open Market | 2,222 | $40K | 12/15/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
TRAX Announces $200M Private Placement and Analyst Upgrades
First Tracks Biotherapeutics announced a $200 million private placement of shares at $32.75 each to institutional investors. Following this capital raise and recent trial data for ANB033, several firms including Leerink Partners, Evercore ISI, and Canaccord Genuity raised their price targets. The stock currently trades within its 52-week range, with an average analyst target of $74.17.
TRAX Announces $200M Private Placement and Analyst Upgrades. First Tracks Biotherapeutics announced a $200 million private placement of shares at $32.75 each to institutional investors. Following this capital raise and recent trial data for ANB033, several firms including Leerink Partners, Evercore ISI, and Canaccord Genuity raised their price targets. The stock currently trades within its 52-week range, with an average analyst target of $74.17.